News

UCB’s Rystiggo (rozanolixizumab-noli) and Zilbrysq (zilucoplan) have gained public reimbursement coverage across multiple Canadian provinces for adults with generalized myasthenia gravis (gMG). Product listing agreements are now in place in British Columbia, Québec, Alberta, Saskatchewan, Nova Scotia, and Newfoundland and Labrador for both therapies, and in Ontario…

Vyvgart (efgartigimod alfa-fcab) improves muscle strength and daily functioning in adults with generalized myasthenia gravis (gMG) who are positive for self-reactive antibodies against the acetylcholine receptor (AChR) protein, regardless of patient and disease features or simultaneous treatments. Those are the main findings of a subgroup analysis of data…

The immunosuppressant tacrolimus as a standalone therapy may help adults with mild or moderate myasthenia gravis (MG) reach and maintain a state of minimal disease symptoms (remission), according to a study in China. Patients whose symptoms began at age 70 or younger were significantly more likely to achieve…

Regulators in the U.S. and the European Union have agreed to review applications seeking approval of Regeneron Pharmaceuticals‘ cemdisiran to treat adults with generalized myasthenia gravis (gMG) who have self-reactive antibodies targeting the acetylcholine receptor (AChR) protein. Further, the U.S. Food and Drug Administration (FDA) has granted the application…

The free June 30 webinar was a space to hear patients share practical advice on managing daily life with myasthenia gravis.

A simple model that uses five clinical factors could help doctors predict which people with ocular myasthenia gravis (OMG) are most likely to achieve minimal symptoms or better within one year, according to a study in China. “Based on prognostic predictions, early efforts can be made to develop therapeutic interventions…

Ublituximab-xiiy, an approved medication for certain types of multiple sclerosis (MS), was shown to safely and effectively reduce disease severity in people with myasthenia gravis (MG) who have self-reactive antibodies against the acetylcholine receptor (AChR) protein. That’s according to new data from an early-stage clinical trial that tested the…

The infusion therapy Imaavy (nipocalimab) is now approved in the U.K. for treating people ages 12 and older with generalized myasthenia gravis (MG). The new authorization by the Medicines and Healthcare Products Regulatory Agency (MHRA), the body that regulates the use of medications in Great Britain, allows the…

For most people with mild, stable myasthenia gravis (MG), taking a low dose of trazodone hydrochloride, an oral antidepressant also commonly used as a sleep aid, can help ease insomnia —difficulty falling asleep, staying asleep, or waking up too early — without worsening MG symptoms or causing breathing…

People with myasthenia gravis (MG) who lack detectable MG-related antibodies, known as seronegative MG, may be rarer than previously suggested, according to a single-center study in Denmark. Researchers identified seronegative MG in only 4.3% of 350 cases — a percentage lower than the roughly 10% reported in earlier studies.